Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.90 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.59 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.55 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696027 | 0.95 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL2430254 | 0.94 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL2429398 | 0.90 | MAP2K1 (0.90) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL2436858 | 0.86 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL2436573 | 0.86 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL697484 | 0.84 | MAP2K1 (0.79) | MAP2K1MAP2K2 | |
| SCHEMBL695855 | 0.84 | MAP2K1 (0.81) | MAP2K1MAP2K2 | |
| SCHEMBL698606 | 0.84 | MAP2K1 (0.80) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL2437770 | 0.84 | MAP2K1 (0.80) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL2434457 | 0.83 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | claimed |
| EP-2227469-A1 | MAPK/ERK KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-09-15 | — | — | EP | claimed |
| WO-2009064675-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-22 | — | — | WO | claimed |
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-14 | — | — | US | claimed |
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | disclosed |
| EP-2227469-A1 | MAPK/ERK KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009064675-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064675-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-22 | — | — | WO | disclosed |
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | MAP2K1 46/4885MAP2K2 43/4885MAP2K5 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.